Novo Nordisk begins study of Lexicon oral obesity drug

The study is investigating the safety and tolerability of LX9851, how it moves through the body and its physiological and biological impacts.
FiercePharma

Persistent Lexicon still working to get an audience with FDA on Type 1 diabetes prospect

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
Seeking Alpha

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...
GEN

Lexicon Fires Back after Sanofi Ends Up-to-$1.7B Diabetes Collaboration

Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...

Lexicon Pharmaceuticals, Inc.: Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential ...
Bloomberg L.P.

How to build smarter lexicons

Designing effective lexicons is a critical component of any communications surveillance program, yet even mature teams encounter avoidable pitfalls that diminish accuracy, create operational strain, ...